Clinical Edge Journal Scan

Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RA


 

Key clinical point: The administration of low-dose glucocorticoids over 2 years resulted in a modest weight gain of ~1 kg but had no effect on blood pressure (BP) in patients with early and established rheumatoid arthritis (RA).

Major finding: After 2 years, participants in both the low-dose glucocorticoid and control groups gained weight, but the low-dose glucocorticoid group gained an additional 1.1 kg of body weight (P < .001), with no significant between-group differences in the mean arterial pressure (P = .187).

Study details: Findings are from a pooled analysis of five randomized controlled trials including 1112 patients with early and established RA who received low-dose glucocorticoids (7.5 mg/day of prednisone equivalent; n = 548) or control treatment (n = 564) over at least 2 years.

Disclosures: This study did not receive any specific funding. Some authors declared receiving investigator fees, grants or contracts, consulting fees, payments or honoraria, or support for attending meetings or travel from or owning stocks or options in various sources.

Source: Palmowski A et al. The effect of low-dose glucocorticoids over two years on weight and blood pressure in rheumatoid arthritis: Individual patient data from five randomized trials. Ann Intern Med. 2023 (Aug 15). doi: 10.7326/M23-0192

Recommended Reading

Opioids not safer than NSAID in patients with RA
MDedge Rheumatology
Lung volume loss at acute exacerbation of RA-ILD tied to increased mortality
MDedge Rheumatology
Patients with RA remain at higher risk for COVID-19-related adverse outcomes even in SARS-CoV-2 Omicron era
MDedge Rheumatology
Rheumatology trials seem vulnerable to unblinding: Report
MDedge Rheumatology
Slight weight gain, no blood pressure increase with low-dose steroids for RA
MDedge Rheumatology
Medicare announces 10 drugs targeted for price cuts in 2026
MDedge Rheumatology
ACR releases guideline for managing ILD in patients with rheumatic disease
MDedge Rheumatology
Commentary: Cardiovascular risk, anti-drug antibodies, and prednisolone in RA, September 2023
MDedge Rheumatology
Precision blood test for rheumatoid arthritis receives Medicare coverage
MDedge Rheumatology
Early glucocorticoid bridging in RA supported by meta-analysis, but concerns remain
MDedge Rheumatology